D espite epidemiological studies showing that increased levels of high-density lipoprotein cholesterol (HDL-C) are associated with a reduced risk of future coronary heart disease, neither monogenic diseases characterized by extreme HDL-C levels nor genetic variants associated with higher HDL-C levels are associated with coronary heart disease risk reduction. 1, 2 Most importantly, increasing HDL-C levels as a therapeutic approach to reduce cardiovascular risk has been called into question by the recent failure of several randomized trials in which therapies aimed at increasing HDL-C levels, such as niacin and cholesteryl ester transferase protein inhibitors, have failed to improve cardiovascular outcomes. [3] [4] [5] 
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However, it remains clear that HDL has multiple potential antiatherogenic functions, 6 including its well-described role in reverse cholesterol transport (RCT) 7 (Figure [A] ). Thus, a novel approach toward coronary heart disease prevention and HDL-targeting therapies focuses on enhancing HDL function rather than HDL-C levels. That cholesterol efflux capacity of HDL isolated from human subjects is inversely correlated with coronary heart disease status 8 reinforces the concept that atheroprotection is associated with HDL function rather than HDL-C levels. In this issue of Arteriosclerosis Thrombosis and Vascular Biology, Gille et al 9 present evidence that in healthy volunteers, infusion of CSL112, a reconstituted HDL (rHDL) containing apolipoprotein AI (apoAI) and phospholipids improves biomarkers of RCT and cholesterol efflux when measured ex vivo.
During the first step in RCT, lipid-poor apoAI particles (also called pre-β particles or nascent HDL) interact with the membrane-bound ATP-binding cassette transporter A1 (ABCA1) to accept free cholesterol from cells, such as macrophages in the arterial wall. The free cholesterol is then esterified by lecithin cholesterol acyltransferase 10 to facilitate the formation of mature HDL that in turn can accept cholesterol via other transporters. Animal studies have shown that either apoAI overexpression or treatment with a bolus of rHDL removes cholesterol from plaques reversing the atherosclerotic process. 11, 12 rHDL containing either apoAI Milano or wild-type apoAI results in similar plaque regression. 13, 14 Furthermore, high-dose single bolus rHDL infusions lead to acute plaque stabilization in animals, 15 suggesting that a rapid, dynamic change in HDL level and efflux may lead to plaque stabilization.
Several rHDL formulations have been used in human studies. In patients with acute coronary syndrome, rHDL infusions composed of either apoAI Milano 16 or wild-type apoAI 17, 18 reduced atheroma volume assessed by intravascular ultrasound compared with baseline values. However, no significant changes were found as compared with placebo groups. It is possible that in the context of acute coronary syndrome, biomarkers of plaque stability or RCT may be more relevant than atheroma volume. Interestingly, in patients with peripheral vascular disease, infusion of the CSL112 predecessor, CSL-111, resulted in decreased lipid content of excised femoral plaque as well as decreased inflammatory markers as compared with saline. 19 Furthermore, infusion of rHDL containing a recombinant pro-apoAI has been shown to stimulate fecal steroid secretion in humans, suggesting upregulation of RCT. 20 The present work by Gille et al 9 provides strong evidence that infusion of CSL112 markedly improves ex vivo cholesterol efflux capacity, the most accurate measure of the RCT pathway available today. Although total cholesterol efflux capacity is increased, the largest increase occurs in ABCA1dependent efflux, which likely reflects the significant acute, dose-dependent increases in circulating pre-β particles, the preferred ABCA1 substrate. The increase in pre-β particles is likely a consequence of the participation of rHDL in HDL remodeling (Figure [B] ). rHDL, with a composition similar to that of CSL112, has been shown to affect the activity of several key proteins in HDL metabolism and promote the production of pre-β particles. 21, 22 As expected, the initial rise in circulating cholesterol occurs as free cholesterol, with a peak reached 2 to 4 hours after the start of the CSL112 infusion. Interestingly, the peak in cholesteryl esters is observed at 24 hours, suggesting that lecithin cholesterol acyltransferase may be a limiting factor. As esterification by lecithin cholesterol acyltransferase enhances the ability of HDL to accept cholesterol and may contribute to RCT, 23 it would be interesting to assess whether the concomitant administration of CSL112 with recombinant lecithin cholesterol acyltransferase may enhance the amount of cholesterol mobilized over time.
A limitation of this work is that cholesterol efflux capacity measured ex vivo remains a surrogate marker of RCT. In addition, significant improvements in cholesterol efflux capacity and RCT may or may not result in a reduction in major adverse cardiac events in the months subsequent to an acute coronary syndrome. Studies will need to be performed in patients with acute coronary syndrome to assess the efficacy and safety of this strategy.
It is also important to consider that HDL-based therapies may have therapeutic effects extending beyond cholesterol efflux and RCT. Indeed, anti-inflammatory and nitric oxide promoting functions of HDL as well as improvements in glucose metabolism have been observed in patients receiving rHDL infusions. 19, [24] [25] [26] Alternatively, rHDL infusion has also been shown to have direct cardiac effects and can cause shortening of the QT interval, prolongation of which is associated with sudden cardiac death. 27 In summary, unlike other therapies that increased HDL-C levels but failed to improve clinical outcomes in randomized controlled trials, rHDL therapies have the potential to reduce coronary disease and stabilize atherosclerotic plaque by improving cholesterol efflux and RCT. Further studies will determine the safety and efficacy of CSL112 in the acute coronary syndrome population, and whether CSL112 may have a broader role in stable coronary artery disease or diseases such as type 2 diabetes mellitus, arthritis, or heart failure. Although significant work remains to be done, there is reason for optimism about this approach as a promising new therapy.
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Figure.
A, Reverse cholesterol transport. Apolipoprotein AI (apoAI; synthesized in the liver and intestines) acquires phospholipid and a small amount of free cholesterol via the ATP-binding cassette transporter A1 (ABCA1) to form nascent pre-β-high-density lipoprotein (HDL). Pre-β-HDL is the preferred acceptor of cholesterol effluxed by ABCA1 and acquires additional lipids from peripheral cells such as macrophages in the arterial wall. Lecithin cholesterol acyltransferase (LCAT) esterifies free cholesterol (FC) to hydrophobic cholesteryl esters (CE), which migrate into the HDL core, driving the maturation of HDL into spherical α particles. Mature HDL particles are able to acquire additional lipids via other pathways, such as those mediated by ABCG1 or scavenger receptor class B member 1 (SR-BI), or by a passive diffusion process. Cholesterol carried on HDL can be delivered directly to the liver via SR-BI. Alternatively, cholesteryl ester present on HDL can be exchanged for triglycerides by cholesteryl ester transferase protein (CETP), transferred to apoBcontaining lipoproteins and delivered to the liver via the LDL receptor (LDLR). Once in the liver, cholesterol can be excreted with the bile, either as free cholesterol or after being converted to a bile salt. B, HDL remodeling. HDL is constantly remodeled in the circulation by numerous enzymes and proteins. Nascent pre-β-HDL acquires free cholesterol by ABCA1. HDL-free cholesterol is esterified by LCAT, to form mature HDL that can acquire more cholesterol. Mature HDL particles can acquire phospholipids (PL) via the phospholipid transfer protein (PLTP) and unload their lipid cargo by several mechanisms: via CETP that transfer cholesteryl ester to apoB-containing lipoproteins; via endothelial lipase (EL) and hepatic lipases (HL) that can hydrolyze phospholipids and triglycerides, respectively; and via liver SR-BI that can selectively uptake cholesterol. Through this process, HDL particles lose volume and apoAI dissociate, regenerating lipid-poor, nascent pre-β-HDL. Insufficiently lipidated apoAI is catabolized by the kidney. Infusion of reconstituted HDL (rHDL) is associated with increased production of nascent, pre-β-HDL, possibly favoring HDL remodeling and decreasing apoAI renal catabolism.
